CCL2 was previously shown to act as a paracrine and autocrine growth factor for prostate cancer cells, and in a small cohort of 83 prostate cancers, it was suggested that CCL2 tissue expression was associated with advanced pathologic stage; however, the study did not include any data on tumour progression or patient outcome [27]. Here, CCL2 is linked to prostate carcinoma.